These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9056587)

  • 1. Some thoughts on individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):41-8. PubMed ID: 9056587
    [No Abstract]   [Full Text] [Related]  

  • 2. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis for bioequivalence review.
    Chow SC; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual bioequivalence--a regulatory update.
    Chen ML
    J Biopharm Stat; 1997 Mar; 7(1):5-11. PubMed ID: 9056581
    [No Abstract]   [Full Text] [Related]  

  • 5. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report supports FDA's bioequivalence evaluation criteria, advocates more stringent statistical testing.
    Clin Pharm; 1988 May; 7(5):334,7. PubMed ID: 3383540
    [No Abstract]   [Full Text] [Related]  

  • 8. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group.
    Williams RL; Patnaik RN; Chen ML
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for the two one-sided tests procedure in bioequivalence.
    Liu JP; Chow SC
    J Pharmacokinet Biopharm; 1992 Feb; 20(1):101-4. PubMed ID: 1588502
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A two one-sided tests procedure for assessment of individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic bioequivalence: a scientific consensus needed.
    Am Fam Physician; 1987 Feb; 35(2):91, 95. PubMed ID: 3812175
    [No Abstract]   [Full Text] [Related]  

  • 18. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striving for standards in bioequivalence assessment: a review.
    Schulz HU; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Aug; 29(8):293-8. PubMed ID: 1743802
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.